About neurosense therapeutics ltd - NRSN
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.
NRSN At a Glance
Neurosense Therapeutics Ltd.
11 HaMenofim Street
Herzliya, Tel Aviv 4672562
| Phone | 972-9-799-6183 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -11,125,000.00 | |
| Sector | Health Technology | Employees | 16 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
NRSN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.766 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.009 |
NRSN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -695,312.50 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NRSN Liquidity
| Current Ratio | 0.309 |
| Quick Ratio | 0.309 |
| Cash Ratio | 0.085 |
NRSN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -397.109 |
| Return on Equity | -2,174.976 |
| Return on Total Capital | 800.36 |
| Return on Invested Capital | -2,031.963 |
NRSN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -12.23 |
| Total Debt to Total Assets | 16.537 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -5.18 |